Seeking Alpha

filoblack

filoblack
Send Message
View as an RSS Feed
View filoblack's Comments BY TICKER:
Latest  |  Highest rated
  • Wall Street Is Overlooking Intellipharmaceutics- CFO Shameze Rampertab Tells Us Why [View article]
    Thanks for posting this interview article, and presenting a major view of what the CFO knows.
    I am long IPCI. I've been in since before the FDA approval, and it is nice to have revenue coming in.
    If IPCI decides to bring Rexista Oxy to the market themselves, it will be a major turning point for the company and would out them on the road to being worth billions down the road.
    I'm just the patient one watching the stock go tick tock, tick, tock. Seen this before, it will be of tremendous value in the near future.
    Jul 31 09:13 PM | Likes Like |Link to Comment
  • Intellipharmaceutics International EPS of $0.09 [View news story]
    Excellent!
    Apr 23 06:21 PM | Likes Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    Thanks for the info.
    Apr 18 03:38 PM | Likes Like |Link to Comment
  • Intellipharmaceutics Announces First Quarter 2014 Results [View article]
    Great news!
    Apr 14 07:35 AM | Likes Like |Link to Comment
  • Innovation And Extensive Patent Portfolio Make ARRAYIT Future Look Bright [View instapost]
    Thanks for your instablog. Hope they can really become diagnostics company. Seems they are headed that way with the new move to a larger facility.
    Mar 19 12:32 AM | Likes Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    This is almost comical. If it wasn't for the alerts I receive via e-mail I would definitely ignore them completely. There seems to be an ongoing issue here about a $15M milestone payment, written by the author of this article. This article is his opinion. Readers are to take it as such and conduct their own research. More importantly, if facts aren't stated by the company via PR or any other verifiable/regulatory means, then assume it is false.
    Having ongoing arguments about past opinion articles, in my opinion, is frivolous discussion. The only thing that matters is what the company is doing right now and what the business plan is in the future.
    The fact is that they have an FDA approved drug now.
    The fact is that they have multiple drugs under review/pending decisions.
    The fact is that they have ongoing studies.
    The fact is Intellipharmaceutics is seeking partnerships for the other drugs in the pipeline.
    The fact is there is an ATM offering which is better than the past offerings executed.
    The fact is that the share price is over %60 from a few months ago, well at least it is for me.
    A person would have to be a moron and not see that there is extreme potential in this stock.
    Good luck to all.
    These are my opinion and feel free to comment, but I will not respond. I just wanted to give my few cents.
    Dec 22 12:46 AM | Likes Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    Sorry you got burned and are upset. I don't think you did your DD and fully understand what the company's goals are. You should revisit your research and understand the company's business objectives are related to the Generic pipeline. Your pump and dump claims are false. The only news released has been factual and about operations. We'll hear more news soon.
    Dec 8 07:43 PM | Likes Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    This is just the beginning.
    Nov 20 10:27 AM | Likes Like |Link to Comment
  • Intellipharmaceutics / Par to Make Immediate Commercial Launch of 15 and 30 mg Generic Focalin XR(R) [View article]
    Nice!
    Nov 18 10:05 PM | Likes Like |Link to Comment
  • Arrayit Well-Positioned To Capitalize On Growth In Genetic Testing Market [View article]
    Hopefully they can use his name and the developments that have been promised since 2009 start coming into reality.
    Oct 17 03:44 AM | 2 Likes Like |Link to Comment
  • Arrayit Well-Positioned To Capitalize On Growth In Genetic Testing Market [View article]
    Good article.
    Oct 15 12:36 PM | Likes Like |Link to Comment
  • Obamacare To Boost Spending On Medical Tests [View instapost]
    Long ARYC.
    Aug 27 01:50 AM | Likes Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    The management are well respected highly intelligent innovators in their career. They have succeeded in other companies and are major holders, along with other institutional investors, in IPCI. They have also funded the company from their own holding company.
    Aug 23 10:30 PM | 1 Like Like |Link to Comment
  • IntelliPharmaCeutics - Primed For An Easy Double [View article]
    IPCI is a growth company with current ANDA filings and future NDA filings. There is no conspiracy, although some large influential pharmaceutical companies obviously receive priority, it still does not prove any agenda against IPCI. The facts that Bhtaylor29 pointed out are true. From what I have researched, the FDA has a very large backlog of ANDA applications in review, and they have a less money due to budget cuts. That's why they raised the GDUFA user fees. Fewer resources to address a large backlog means that approvals will take longer. So, they hope to bring down the size of the backlog using the new user fees.
    A lower FDA budget affects growth companies like IPCI that are waiting on their first approval, and slows the introduction of generic drugs into the market which will help lower health care costs.
    I've been following IPCI for a long time and I have concluded that it is low risk, just because of the number of ANDA applications they have in review. Even if they were not to receive approval for the First ANDA, in time they will receive approval for one of the other generic drugs.
    A short term drug rejection can hurt the stock, but not by too much where it is already trading, but short/long term an approval will catapault the value. However, given all signs pointing to an approval for FocalinXR ANDA, this can really validate the company and the technology they have developed for drug delivery. The partnerships for the other generics, as well ass the NDAs, will be easy and they can negotiate larger up front payments and milestone payments. IPCI is the next billion dollar company in this sector.
    I am long IPCI.
    Aug 22 12:47 PM | 4 Likes Like |Link to Comment
  • ARYC President Dr Schena Discusses Q2 Performance In A Brief Interview [View instapost]
    Thanks for the information. This is a great communications effort. Thanks for your DD CBOE trader.
    Aug 16 01:09 PM | Likes Like |Link to Comment
COMMENTS STATS
20 Comments
10 Likes